Eton Pharmaceuticals, Inc. Chief Financial Officer Judith M. Matthews filed an initial Form 3 disclosing beneficial ownership of an employee stock option linked to 37,000 shares of common stock at an exercise price of $26.05 per share, expiring on April 12, 2036.
According to the disclosure, these employee stock options will vest in four equal installments on April 13 of 2027, 2028, 2029 and 2030, and are held directly by Matthews.
Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported open-market sales of a total of 120,000 shares of common stock on May 28, 2026. The transactions were executed at weighted-average prices, with individual trade prices ranging from $31.59 to $32.55 per share.
Following these sales, Brynjelsen directly held about 833,694 shares of Eton common stock. The filing notes that full details of the number of shares sold at each separate price are available upon request from the company, the SEC staff, or any security holder.
The Charles Schwab Corporation files a Form 144 notice proposing sale of 120,000 common shares for an aggregate amount of $3,888,000.00. Shares outstanding were 27,392,358 as of 05/28/2026, and the securities are listed on NASDAQ. The filing lists prior issuances and purchases dated 05/17/2017, 08/13/2019, 06/03/2021, and 08/21/2021.
Eton Pharmaceuticals Chief Business Officer David Krempa exercised stock options and sold shares in several open-market trades. On May 22–27, 2026, he exercised options to acquire 87,794 shares of common stock at exercise prices of $1.37–$3.58 per share and sold 100,000 shares in open-market transactions at weighted average prices in the low-to-mid $30s, as detailed in the filing.
Following these transactions, he holds 25,249 shares of Eton common stock directly and retains 118,406 employee stock options, according to the reported post-transaction balances.
ETON Rule 144 disclosure: This excerpt lists transferrable equity granted by the issuer and related quantities and dates. It shows multiple equity items including RSUs and Options with specific grant or event dates and share counts, and references Nasdaq as the market.
Eton Pharmaceuticals entered a supply and distribution agreement for exclusive U.S. commercialization rights to IMPAVIDO (miltefosine), an orphan drug for various forms of leishmaniasis. The initial term runs through March 31, 2032, with options for up to ten additional one-year renewals.
Eton will pay the supplier $4.25 million in fixed fees during the initial term and up to an additional $4.0 million tied to cumulative net sales milestones of $50 million, $100 million, $150 million and $200 million. The supplier receives 55% of net sales up to $7.0 million per year and 50% above that, while covering product and regulatory costs; Eton funds sales and marketing. Eton’s exclusive U.S. rights begin on September 26, 2026, and 2025 U.S. sales of IMPAVIDO were $8.1 million.
Eton Pharmaceuticals reported a profitable quarter for the three months ended March 31, 2026, with total revenues of $24,266 and net income of $1,554, compared with a net loss a year earlier. Revenue was driven by higher product sales and royalties, especially from INCRELEX®, GALZIN®, ALKINDI SPRINKLE®, Carglumic Acid and the addition of KHINDIVI™. Licensing revenue declined because the prior year included one-time INCRELEX® out-licensing and DS-200 milestone payments. Gross profit rose to $14,735 as product sales expanded, while operating expenses increased mainly from higher FDA fees and headcount.
Cash from operating activities strengthened to $7,405, but overall cash declined to $19,661 after $15,075 of investing outflows, largely a $14,000 upfront payment for U.S. rights to HEMANGEOL® and a $1,000 IPR&D license. The balance sheet shows $97,710 in total assets, including $43,738 of intangible assets related to acquired rare disease products, and $30,747 of SWK term debt. Management highlighted non-GAAP adjusted EBITDA of $5,709 and non-GAAP net income of $4,482, reflecting add-backs for amortization, stock-based compensation and inventory step-up.
Eton Pharmaceuticals reported strong first-quarter 2026 results, with total net revenue of $24.3 million, up 40% from $17.3 million a year earlier, and product sales and royalties rising 73% to $24.3 million. Gross profit increased to $14.7 million from $9.9 million.
The company generated Adjusted EBITDA of $5.7 million, or 24% of revenue, versus $3.7 million and 21% a year ago. GAAP results swung to net income of $1.6 million from a $1.6 million loss, while non-GAAP net income rose to $4.5 million. Eton raised its 2026 revenue outlook to more than $120 million and now targets at least a 30% Adjusted EBITDA margin, supported by record product sales, launches of DESMODA and HEMANGEOL, and continued rare-disease pipeline progress.
Eton Pharmaceuticals filed a report describing the relaunch of HEMANGEOL (propranolol) Oral Solution, the only FDA‑approved treatment for infantile hemangioma, a rare pediatric vascular tumor that can be time‑sensitive.
The relaunch integrates the full Eton Cares patient support program, including $0 co‑pay for eligible commercially insured patients and expanded patient assistance. HEMANGEOL is an orphan drug typically started between five weeks and five months of age and used for about six months to help prevent complications. The company estimates approximately 5,000–10,000 infants in the United States are treated with HEMANGEOL each year and is using an exclusive rare disease specialty pharmacy distribution model to support timely access.
Eton Pharmaceuticals filed an 8-K to announce dosing of the first patient in a pilot clinical study of ET-700, its extended-release zinc acetate candidate for Wilson disease. The double-blinded, placebo-controlled trial in Denmark will follow 36 healthy volunteers over four weeks using 64Cu PET imaging to measure intestinal copper absorption.
The study compares GALZIN 50 mg three times daily, ET-700 75 mg twice daily plus one placebo dose, and placebo three times daily, with hepatic 64Cu uptake as the primary endpoint. Eton’s CEO said that, if approved, ET-700 could potentially exceed $100 million in peak annual U.S. sales and support simpler dosing for this lifelong condition.